Patents by Inventor Mark Mercola

Mark Mercola has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20140243387
    Abstract: The present invention relates to regulation of cardiac contractile function. The present invention is based on the discovery that microRNAs contribute to the loss of cardiac contractility. Specifically, miR-25 binds to SERCA2a which results in a loss of function and interferes with Ca2+ handling. Accordingly, the present invention relates to methods of increasing cardiac contractile function by inhibiting miR-25. The invention further provides methods to identify agents that can modulate miR-25 activity, including high throughput screening methods, and provides a means to identify agents that are useful for treating patients having cardiac contractile function associated disorders.
    Type: Application
    Filed: December 17, 2013
    Publication date: August 28, 2014
    Applicants: Icahn School of Medicine at Mount Sinai, Sanford-Burnham Medical Research Institute
    Inventors: Mark Mercola, Agustin Rojas-Munoz, Christine Wahlquist, Alexandre Colas, Roger J. Hajjar, Dongtak Jeong
  • Publication number: 20130190258
    Abstract: Methods and small molecule compounds for inhibition of cancer cell proliferation are provided. One example of a class of compounds that may be used is represented by the compound of Formula I or a pharmaceutically acceptable salt, N-oxide or solvate thereof, wherein A, B, D, E, F, G, I, J, R, R1, R2, R2?, R3, R4, R5, R6, R7, R8, R9 are as described herein.
    Type: Application
    Filed: January 24, 2013
    Publication date: July 25, 2013
    Inventors: John CASHMAN, Mark MERCOLA, Dennis SCHADE, Masanao TSUDA
  • Publication number: 20130177535
    Abstract: Methods and small molecule compounds for stem cell differentiation and treatment of animals with diseases are provided. One example of a class of compounds that may be used is represented by the compound of Formula I and II: or a pharmaceutically acceptable salt or solvate thereof, wherein A, X, Q, R1, R2, R3, R4 are as described herein.
    Type: Application
    Filed: July 2, 2012
    Publication date: July 11, 2013
    Inventors: John Cashman, Marion Lanier, Mark Mercola, Dennis Schade, Erik Willems
  • Publication number: 20130157947
    Abstract: Small molecule compounds and methods for stem cell differentiation are provided herein. An example of a class of compounds that may be used to practice the methods disclosed herein is represented by enantiomerically pure isomers of compounds of Formula I: or a chirally pure stereoisomer, pharmaceutically acceptable salt, or solvate thereof, wherein R1, R2, R3, R4, R5, R5?, R6, R6?, R7, R7? are as described herein.
    Type: Application
    Filed: March 23, 2012
    Publication date: June 20, 2013
    Inventors: MARK MERCOLA, John Cashman, Marion Lanier, Erik Willems, Dennis Schade
  • Patent number: 8168391
    Abstract: The present invention provides screening methods for the detection of agents that affect various aspects of ?-cell biology, particularly insulin gene expression. Screening methods are also provided for detection of agents that affect ?-cell differentiation from progenitor cells. Additionally, agents identified using such methods are provided and are useful for increasing insulin gene expression and reducing lipotoxicity.
    Type: Grant
    Filed: November 7, 2008
    Date of Patent: May 1, 2012
    Assignees: Burnham Institute for Medical Research, The Regents of the University of California
    Inventors: Fred Levine, Pamela Itkin-Ansari, Mark Mercola
  • Publication number: 20110318775
    Abstract: The present invention provides a method, system and composition for screening drug candidates for cardiotoxicity and for novel drugs that effect cardiomyocyte contractility and function. The invention provides an efficient and reliable screening assay to detect the effect of new and potential drug candidates on cardiomyocyte calcium flux, membrane depolarization, and/or the propagation of action potentials.
    Type: Application
    Filed: December 3, 2010
    Publication date: December 29, 2011
    Applicant: Sanford-Burnham Medical Research Institute
    Inventors: Mark Mercola, Fabio Cerignoli, Jeffrey Price
  • Publication number: 20110281356
    Abstract: Methods and small molecule compounds for stem cell differentiation are provided. One example of a class of compounds that may be used is represented by the compound of Formula I: or a pharmaceutically acceptable salt or solvate thereof, wherein R1, R2, R3, R4, R5, R5?, R6, R6?, R7, R7? are as described herein.
    Type: Application
    Filed: May 13, 2011
    Publication date: November 17, 2011
    Applicants: Human BioMolecular Research Institute, Sanford-Burnham Medical Research Institute
    Inventors: Mark Mercola, John Cashman, Marion Lanier, Erik Willems
  • Patent number: 8039255
    Abstract: The finding that Dickkopf1 (Dkk1) is a dual function protein demonstrates a mechanism for the coordination of cell migration and antagonism of Wnt/?-catenin signaling during developmental and pathological processes. The profile of Dkk proteins expressed by human breast cancers correlates with indicators of outcome: Dkk1 associates with markers of poor prognosis whereas expression of single function Dkk2 or Dkk3 (which inhibit Wnt/?-catenin signaling and promote migration, respectively) correlates with phenotypes reflective of good prognosis. Therefore, the pro-migratory activities of Dkk1 and 3 identified here offer new insights into breast cancer progression and a potential avenue for therapeutic intervention.
    Type: Grant
    Filed: November 1, 2010
    Date of Patent: October 18, 2011
    Assignee: The Burnham Institute
    Inventors: Mark Mercola, Ruchika Gupta
  • Patent number: 7910305
    Abstract: Compositions and methods are provided for screening for compounds that modulate insulin promoter activity. Vectors that express green fluorescent protein under the control of the human insulin promoter are introduced into mouse and human cells in which the insulin promoter is expressed in a glucose-responsive manner. Such cells are then used to screen for compounds that modulate insulin promoter activity.
    Type: Grant
    Filed: September 14, 2006
    Date of Patent: March 22, 2011
    Assignee: The Burnham Institute for Medical Research
    Inventors: Mark Mercola, Fred Levin, Pamela Itkin-Ansari
  • Publication number: 20110039335
    Abstract: The finding that Dickkopf1 (Dkk1) is a dual function protein demonstrates a mechanism for the coordination of cell migration and antagonism of Wnt/?-catenin signaling during developmental and pathological processes. The profile of Dkk proteins expressed by human breast cancers correlates with indicators of outcome: Dkk1 associates with markers of poor prognosis whereas expression of single function Dkk2 or Dkk3 (which inhibit Wnt/?-catenin signaling and promote migration, respectively) correlates with phenotypes reflective of good prognosis. Therefore, the pro-migratory activities of Dkk1 and 3 identified here offer new insights into breast cancer progression and a potential avenue for therapeutic intervention.
    Type: Application
    Filed: November 1, 2010
    Publication date: February 17, 2011
    Inventors: Mark Mercola, Ruchika Gupta
  • Patent number: 7833980
    Abstract: The finding that Dickkopf1 (Dkk1) is a dual function protein demonstrates a mechanism for the coordination of cell migration and antagonism of Wnt/?-catenin signaling during developmental and pathological processes. The profile of Dkk proteins expressed by human breast cancers correlates with indicators of outcome: Dkk1 associates with markers of poor prognosis whereas expression of single function Dkk2 or Dkk3 (which inhibit Wnt/?-catenin signaling and promote migration, respectively) correlates with phenotypes reflective of good prognosis. Therefore, the pro-migratory activities of Dkk1 and 3 identified here offer new insights into breast cancer progression and a potential avenue for therapeutic intervention.
    Type: Grant
    Filed: December 11, 2008
    Date of Patent: November 16, 2010
    Assignee: The Burnham Institute
    Inventors: Mark Mercola, Ruchika Gupta
  • Publication number: 20100286220
    Abstract: Disclosed are methods and compositions relating to antagonists of HNF4?.
    Type: Application
    Filed: April 30, 2010
    Publication date: November 11, 2010
    Applicants: Burnham Institute for Medical Research, Regents of the University of California
    Inventors: Fred Levine, Mark Mercola, Suzette Farber-Katz, Marcia I. Dawson, Pamela Itkin-Ansari
  • Publication number: 20100159596
    Abstract: Methods and small molecule compounds for stem cell differentiation are provided.
    Type: Application
    Filed: September 16, 2009
    Publication date: June 24, 2010
    Applicants: Burnham Institute for Medical Research, Human BioMolecular Research Institute
    Inventors: Mark Mercola, Marcia Dawson, John Cashman
  • Publication number: 20090264309
    Abstract: Compositions and methods are provided for screening for compounds that modulate insulin promoter activity. Vectors that express green fluorescent protein under the control of the human insulin promoter are introduced into mouse and human cells in which the insulin promoter is expressed in a glucose-responsive manner. Such cells are then used to screen for compounds that modulate insulin promoter activity.
    Type: Application
    Filed: September 14, 2006
    Publication date: October 22, 2009
    Inventors: Mark Mercola, Fred Levine
  • Publication number: 20090215690
    Abstract: The finding that Dickkopf1 (Dkk1) is a dual function protein demonstrates a mechanism for the coordination of cell migration and antagonism of Wnt/?-catenin signaling during developmental and pathological processes. The profile of Dkk proteins expressed by human breast cancers correlates with indicators of outcome: Dkk1 associates with markers of poor prognosis whereas expression of single function Dkk2 or Dkk3 (which inhibit Wnt/?-catenin signaling and promote migration, respectively) correlates with phenotypes reflective of good prognosis. Therefore, the pro-migratory activities of Dkk1 and 3 identified here offer new insights into breast cancer progression and a potential avenue for therapeutic intervention.
    Type: Application
    Filed: December 11, 2008
    Publication date: August 27, 2009
    Inventors: Mark Mercola, Ruchika Gupta
  • Publication number: 20090137543
    Abstract: The present invention provides screening methods for the detection of agents that affect various aspects of ?-cell biology, particularly insulin gene expression. Screening methods are also provided for detection of agents that affect ?-cell differentiation from progenitor cells. Additionally, agents identified using such methods are provided and are useful for increasing insulin gene expression and reducing lipotoxicity.
    Type: Application
    Filed: November 7, 2008
    Publication date: May 28, 2009
    Inventors: Fred Levine, Pamela Itkin-Ansari, Mark Mercola
  • Patent number: 7465585
    Abstract: The finding that Dickkopf1 (Dkk1) is a dual function protein demonstrates a mechanism for the coordination of cell migration and antagonism of Wnt/?-catenin signaling during developmental and pathological processes. The profile of Dkk proteins expressed by human breast cancers correlates with indicators of outcome: Dkk1 associates with markers of poor prognosis whereas expression of single function Dkk2 or Dkk3 (which inhibit Wnt/?-catenin signaling and promote migration, respectively) correlates with phenotypes reflective of good prognosis. Therefore, the pro-migratory activities of Dkk1 and 3 identified here offer new insights into breast cancer progression and a potential avenue for therapeutic intervention.
    Type: Grant
    Filed: April 10, 2007
    Date of Patent: December 16, 2008
    Assignee: The Burnham Institute
    Inventors: Mark Mercola, Ruchika Gupta
  • Publication number: 20040014209
    Abstract: The present invention relates to compositions and methods for stimulating differentiation of stem cells into cardiac cells. The methods of the invention involve contacting a population cells comprising stem cells with at least one Wnt antagonist, such as a polypeptide or polypeptide fragment. In certain embodiments, the methods of the invention involve Dkk proteins or fragments, homologs, derivatives, variants, or peptidomimetics thereof.
    Type: Application
    Filed: January 23, 2003
    Publication date: January 22, 2004
    Inventors: Andrew B. Lassar, Mark Mercola, Ruchika Gupta, Martha Marvin, Valerie Schneider, Eldad Tzahor, Barbara Brott, Sergei Sokol